Amputations for Management of Sarcoma,Trauma,or Chronic InfectionNCT06205745
Quality of Life in Amputated Patients Based on Social Deprivation Factors
An observational study of Amputations for Management of Sarcoma,Trauma,or Chronic Infection, run by University of Florida at 1 site in United States.
Trial summary
The purpose of this study is to investigate the quality of life in patients who previously underwent major amputation, and to determine any correlation with social deprivation factors. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Amputations for Management of Sarcoma,Trauma,or Chronic Infection
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Feb 2024to 30 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Up to 250 patients, 18-90+ years of age, who underwent major amputations for definitive management of their sarcoma, trauma, or chronic infection by our Orthopaedic oncologists (Parker Gibbs Jr., MD, Mark Scarborough, MD, Andre Spiguel, MD). We will determine our participant population using EPIC records of our physicians' case logs. Patients must be at least 6 months postoperative from their amputation to be eligible for contact.
Who may be able to join
- Adult patients who underwent major amputation via orthopaedic oncology attending at UF (transtibial, transfemoral, hip disarticulation, transhumeral, or trans-forearm)
- Must be at least 6 months post amputation at the time of survey administration
- Patients undergoing amputation for sarcoma, trauma, or chronic infection
Who cannot join
- Pediatric patients (<18 years of age)
- Adult patients with the following amputations: ray resection, transmetacarpal, wrist disarticulation, any other amputation distal to the carpi, Syme (ankle disarticulation), Chopart amputation, transmetatarsal, any other amputation distal to the tibia
- Patients undergoing amputations for diabetes or vascular disease
- Patients within 6 months post-operatively from their amputation
Trial locations and contacts
1 site in 1 country.
United States1 site
UF & Shands Orthopaedics and Sports Medicine Institute
Gainesville, Florida, 32607
About this study
The purpose of this study is to investigate the quality of life in patients who previously underwent major amputation, and to determine any correlation with social deprivation factors. We hypothesize that patients with increased social deprivation (public or no insurance, lower education, lower income, etc.) will have lower quality of life following amputation.
Read the detailed description
Amputation remains an important treatment option for patients with sarcoma. While limb salvage procedures have become more widely utilized after the advent of chemotherapy, some patients still require amputation in the management of their disease. Studies have shown that patients with social deprivation factors are at higher risk of presenting with advanced disease, and thus are at increased risk of requiring definitive amputation1-3. Additional research shows amputations are more common in lower socioeconomic status patients4. Whether these procedures are done for trauma or infection, they can have morbid outcomes. Prior literature demonstrates that long-term healthcare costs after amputation are higher than in limb salvage5,6. In some patients, the costs associated with prosthetics may be prohibitive and thus impact quality of life. While many factors are thought to ultimately impact life after amputation7, it remains unclear how social deprivation affects outcomes in patients who undergo an amputation.
Data Collection: Under an approved HIPAA waiver, dependent and independent variables will be collected and retrospectively from a chart review. After we receive the initial request, we will perform a chart review to ensure inclusion/exclusion criteria was met. The following information will be obtained through a combination of the report request and subsequent chart review:
- Demographic Information: Name, MRN, Age, Gender, Insurance Status (private v Medicaid v Medicare v uninsured), Address (including Zip Code), Sarcoma Diagnosis, Amputation Level and Date, Medical Comorbidities
- Survey Information: Current work status and Occupation, Race, Education Level (Highest level degree obtained), Use of prosthesis (and why not if answer is No), Prosthesis Information if yes (Manufacturer and Model), SF-36 Questionnaire, MSTS Tumor Score Questionnaire, Prosthesis Evaluation Questionnaire-Mobility Section (PEQ-MS)
In addition to chart review, subjects will also complete a series of questionnaires to assess outcomes related to surgery. The questionnaires include SF-36 Questionnaire, MSTS Tumor Score Questionnaire, and Prosthesis Evaluation Questionnaire-Mobility Section (PEQ-MS). Prior to contact, subjects will receive a letter (waiver of documentation of informed consent) from the attending physicians describing the study and asking them if they would like to participate in the study by completing the questionnaires and allowing the use of their data for the study. The letter from the attending physicians will also explain that subjects will receive an email or telephone call from a research team member. Subjects will have the opportunity to complete the questionnaire via phone, regular mail, or email using the survey function in RedCap.
Subjects that are willing to complete the questionnaire will be enrolled under a waiver of documentation of informed consent. Subjects that are not willing to complete the questionnaire but will allow their data to be used will be enrolled under a waiver of documentation of informed consent (i.e.: Subject states on the phone they don't want to complete questionnaire, but they give permission for us to retrospectively use their data). Those subjects that have inadequate data or cannot be reached after a reasonable effort will be enrolled under a full waiver of informed consent to use their retrospective data. If subjects indicate on the phone or via email, they do not want their retrospective data used we will withdraw the subject and delete all retrospective data.
Data Analysis: We will perform descriptive statistics on the cohort of patients, as well as report their outcomes. Data will be presented as means and SD for continuous variables and frequencies and percentages for nominal data. We will compare the group of patients with poor outcomes with their counterparts using Student t-tests for continuous variables and Chi square or Fisher exact tests for nominal data.
This study involves minimal risk to patients; however, the patient may experience some psychological and emotional distress when answering questions on the survey. Patients may decline to answer the question or withdraw participation at any time. The investigators will reassure each participant that all survey answers are based on what the participant is feeling and that there is no "correct" answer.
Patients' confidentiality also must be considered during the survey if completed over the phone. However, the study team will establish safeguards to ensure the security and privacy of participants study records. Once all subject data is collected, subject PHI will be removed, and the data will be maintained by using assigned research identification numbers that uniquely identifies each individual. Only IRB approved research personnel will have access to identifiable research data. All recorded data will be labeled using a subject-specific code. A document linking the subject specific code to the name, MRN, relevant dates, e-mail, and telephone number of the subject will be stored securely in a locked cabinet within OSMI and/or electronically on a password-protected server in the University of Florida. All experimental data (defined as all data other than the subject's name, MRN, relevant dates, e-mail address, and telephone number) will only contain the subject-specific code. All data shared with individuals outside the study team will be de-identified, including removal of the subject-specific code
What is being measured
The primary outcome is the main question the study is designed to answer.
SF-36 Questionnaire
A survey set of generic, coherent, and easily administered quality-of-life measures.
Measured: One visit at least 6 months removed from the amputation
MSTS Tumor Score Questionnaire
A physician/patient-completed questionnaire designed to assess functional outcome for patients with sarcomas in the extremities.
Measured: One visit at least 6 months removed from the amputation
Prosthesis Evaluation Questionnaire-Mobility Section (PEQ-MS)
A questionnaire that evaluates the perceived potential for mobility using prosthetic devices over the past 4 weeks
Measured: One visit at least 6 months removed from the amputation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2024
- Study start26 Feb 2024
- Primary completion30 Jun 2025
- Study completion30 Jun 2025
Why it stopped: Staffing constraints
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Amputations for Management of Sarcoma,Trauma,or Chronic InfectionStudies of the same condition, open and under way.
- More trials run by University of FloridaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Florida
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Andre Spiguel, MD, Principal investigator, University of Florida
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06205745
- Sponsor's protocol ID
- IRB202301896
- Status last verified
- Aug 2025
- First submitted
- 4 Jan 2024
- Last updated
- 11 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quality of Life in Amputated Patients Based on Social Deprivation Factors
- ClinicalTrials.gov ID
- NCT06205745
- Acronym / sponsor ID
- IRB202301896
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Staffing constraints
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of FloridaUniversity, hospital or other
- Study start
- 26 Feb 2024 (actual)
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 30 Jun 2025 (actual)
- First posted
- 16 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the quality of life in patients who previously underwent major amputation, and to determine any correlation with social deprivation factors. We hypothesize that patients with increased social deprivation (public or no insurance, lower education, lower income, etc.) will have lower quality of life following amputation.
Detailed description
Amputation remains an important treatment option for patients with sarcoma. While limb salvage procedures have become more widely utilized after the advent of chemotherapy, some patients still require amputation in the management of their disease. Studies have shown that patients with social deprivation factors are at higher risk of presenting with advanced disease, and thus are at increased risk of requiring definitive amputation1-3. Additional research shows amputations are more common in lower socioeconomic status patients4. Whether these procedures are done for trauma or infection, they can have morbid outcomes. Prior literature demonstrates that long-term healthcare costs after amputation are higher than in limb salvage5,6. In some patients, the costs associated with prosthetics may be prohibitive and thus impact quality of life. While many factors are thought to ultimately impact life after amputation7, it remains unclear how social deprivation affects outcomes in patients who undergo an amputation.
Data Collection: Under an approved HIPAA waiver, dependent and independent variables will be collected and retrospectively from a chart review. After we receive the initial request, we will perform a chart review to ensure inclusion/exclusion criteria was met. The following information will be obtained through a combination of the report request and subsequent chart review:
- Demographic Information: Name, MRN, Age, Gender, Insurance Status (private v Medicaid v Medicare v uninsured), Address (including Zip Code), Sarcoma Diagnosis, Amputation Level and Date, Medical Comorbidities
- Survey Information: Current work status and Occupation, Race, Education Level (Highest level degree obtained), Use of prosthesis (and why not if answer is No), Prosthesis Information if yes (Manufacturer and Model), SF-36 Questionnaire, MSTS Tumor Score Questionnaire, Prosthesis Evaluation Questionnaire-Mobility Section (PEQ-MS)
In addition to chart review, subjects will also complete a series of questionnaires to assess outcomes related to surgery. The questionnaires include SF-36 Questionnaire, MSTS Tumor Score Questionnaire, and Prosthesis Evaluation Questionnaire-Mobility Section (PEQ-MS). Prior to contact, subjects will receive a letter (waiver of documentation of informed consent) from the attending physicians describing the study and asking them if they would like to participate in the study by completing the questionnaires and allowing the use of their data for the study. The letter from the attending physicians will also explain that subjects will receive an email or telephone call from a research team member. Subjects will have the opportunity to complete the questionnaire via phone, regular mail, or email using the survey function in RedCap.
Subjects that are willing to complete the questionnaire will be enrolled under a waiver of documentation of informed consent. Subjects that are not willing to complete the questionnaire but will allow their data to be used will be enrolled under a waiver of documentation of informed consent (i.e.: Subject states on the phone they don't want to complete questionnaire, but they give permission for us to retrospectively use their data). Those subjects that have inadequate data or cannot be reached after a reasonable effort will be enrolled under a full waiver of informed consent to use their retrospective data. If subjects indicate on the phone or via email, they do not want their retrospective data used we will withdraw the subject and delete all retrospective data.
Data Analysis: We will perform descriptive statistics on the cohort of patients, as well as report their outcomes. Data will be presented as means and SD for continuous variables and frequencies and percentages for nominal data. We will compare the group of patients with poor outcomes with their counterparts using Student t-tests for continuous variables and Chi square or Fisher exact tests for nominal data.
This study involves minimal risk to patients; however, the patient may experience some psychological and emotional distress when answering questions on the survey. Patients may decline to answer the question or withdraw participation at any time. The investigators will reassure each participant that all survey answers are based on what the participant is feeling and that there is no "correct" answer.
Patients' confidentiality also must be considered during the survey if completed over the phone. However, the study team will establish safeguards to ensure the security and privacy of participants study records. Once all subject data is collected, subject PHI will be removed, and the data will be maintained by using assigned research identification numbers that uniquely identifies each individual. Only IRB approved research personnel will have access to identifiable research data. All recorded data will be labeled using a subject-specific code. A document linking the subject specific code to the name, MRN, relevant dates, e-mail, and telephone number of the subject will be stored securely in a locked cabinet within OSMI and/or electronically on a password-protected server in the University of Florida. All experimental data (defined as all data other than the subject's name, MRN, relevant dates, e-mail address, and telephone number) will only contain the subject-specific code. All data shared with individuals outside the study team will be de-identified, including removal of the subject-specific code
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Up to 250 patients, 18-90+ years of age, who underwent major amputations for definitive management of their sarcoma, trauma, or chronic infection by our Orthopaedic oncologists (Parker Gibbs Jr., MD, Mark Scarborough, MD, Andre Spiguel, MD). We will determine our participant population using EPIC records of our physicians' case logs. Patients must be at least 6 months postoperative from their amputation to be eligible for contact.
Key inclusion criteria (3 listed)
- Adult patients who underwent major amputation via orthopaedic oncology attending at UF (transtibial, transfemoral, hip disarticulation, transhumeral, or trans-forearm)
- Must be at least 6 months post amputation at the time of survey administration
- Patients undergoing amputation for sarcoma, trauma, or chronic infection
Key exclusion criteria (4 listed)
- Pediatric patients (<18 years of age)
- Adult patients with the following amputations: ray resection, transmetacarpal, wrist disarticulation, any other amputation distal to the carpi, Syme (ankle disarticulation), Chopart amputation, transmetatarsal, any other amputation distal to the tibia
- Patients undergoing amputations for diabetes or vascular disease
- Patients within 6 months post-operatively from their amputation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
SF-36 Questionnaire
Time frame: One visit at least 6 months removed from the amputation
A survey set of generic, coherent, and easily administered quality-of-life measures.
MSTS Tumor Score Questionnaire
Time frame: One visit at least 6 months removed from the amputation
A physician/patient-completed questionnaire designed to assess functional outcome for patients with sarcomas in the extremities.
Prosthesis Evaluation Questionnaire-Mobility Section (PEQ-MS)
Time frame: One visit at least 6 months removed from the amputation
A questionnaire that evaluates the perceived potential for mobility using prosthetic devices over the past 4 weeks
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2025.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andre Spiguel, MD principal investigator
University of Florida
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Amputations for Management of Sarcoma,Trauma,or Chronic Infection, run by University of Florida at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 11 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SF-36 Questionnaire (time frame: One visit at least 6 months removed from the amputation). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2025.